2025 cagrilintide semaglutide cagrisema phase 3 results 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Amylin Commands Weight Loss Attention
Description
Historically, there was significant concern for notoriety bias (i.e., increased likelihood of case reporting when patients are exposed to a drug with a negative reputation), which was mitigated by studying disproportionality signals
As always do your own research, look at the studies, and talk to a holistic or functional practitioner if it makes sense for you
Jiang, W
Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation
